Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)
This study has been completed.
Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT00082238
  Purpose

People with CF have a high incidence of diabetes, called CFRD. CFRD is an important cause of worsened morbidity and mortality, thus understanding the pathophysiology underlying its development is imperative. Insulin deficiency has been well recognized as one cause of CFRD; however the clinical presentation and studies of pathogenesis indicate that the etiology is more complex. There is strong evidence that normal metabolism of carbohydrate, protein and fat is altered in CF. We believe that the inflammatory response to chronic underlying lung disease is responsible for insulin resistance and alters substrate metabolism, and that these changes, in addition to insulin deficiency cause CFRD. Our global hypothesis is that hyperglycemia is caused, in part, by high rates of gluconeogenesis resulting from excessive amino acid substrate availability caused by cytokine-mediated protein catabolism. We further hypothesize that inflammation alters normal fatty acid metabolism leading to lipogenesis, an energy wasteful pathway. We will recruit 24 adult CF subjects and 10 controls (similar in distribution in lean tissue mass, age and gender) and will categorize them according to glucose tolerance (OGTT), as well as insulin secretion and insulin sensitivity using the Tolbutamide-stimulated IVGTT and the Minimal Model. Clinical status will be characterized by measuring pulmonary function and modified NIH scores, in addition to measuring levels of circulating cytokines. Gluconeogenesis (GNG) will be quantified by measuring the incorporation 2H into the 2nd, 5th and 6th carbons of glucose. Amino acid turnover rates will be measured using stable isotopes of lactate and alanine and whole body protein turnover (WBPT) will be measured using [1-13C]leucine and [15N2]urea. Fat metabolism will be evaluated by measuring ketone body turnover using stable isotopes, and by quantifying lipogenesis using the isotopomer equilibration method. Key enzymes of fatty acid metabolism will also be measured. We will utilize indirect calorimetry to measure resting energy expenditure. Subjects will be recruited from the CF centers at the University of Texas- Southwestern and the South Central CF Consortium.

Our proposal is intended to better describe the unique metabolism of people with CF, and to provide a comprehensive evaluation of pathophysiologic changes which contribute to the development of CFRD and to wasting; and are part of the applicant's long-range goal which is to identify the underlying causes of CF related diabetes and catabolism so that disease-specific therapies can be developed. We fully expect that the proposed studies will provide new and important information.


Condition Intervention
Cystic Fibrosis
Diabetes Mellitus
Drug: Ibuprofen

Genetics Home Reference related topics: cystic fibrosis
MedlinePlus related topics: Cystic Fibrosis Diabetes
Drug Information available for: Ibuprofen Dexibuprofen
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Non-Randomized, Single Group Assignment, Pharmacokinetics/Dynamics Study
Official Title: Increased Gluconeogenesis is One Cause of CFRD

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Estimated Enrollment: 60
Study Start Date: March 2003
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

cystic fibrosis with any type of glucose tolerance

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00082238

Locations
United States, Texas
University of Texas Southwestern
Dallas, Texas, United States, 75390-9063
Sponsors and Collaborators
  More Information

Study ID Numbers: 58603DK
Study First Received: May 3, 2004
Last Updated: August 19, 2008
ClinicalTrials.gov Identifier: NCT00082238  
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Ibuprofen
Metabolic Diseases
Fibrosis
Diabetes Mellitus
Endocrine System Diseases
Digestive System Diseases
Cystic Fibrosis
Respiratory Tract Diseases
Genetic Diseases, Inborn
Lung Diseases
Pancreatic Diseases
Infant, Newborn, Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders
Cystic fibrosis

Additional relevant MeSH terms:
Pathologic Processes

ClinicalTrials.gov processed this record on January 15, 2009